Distribution of the continuous variables in donors and recipients for first retransplantations, with the results from the Cox univariate analysis, in relation to the 1–5–10 years graft survival.

<p>Distribution of the continuous variables in donors and recipients for first retransplantations, with the results from the Cox univariate analysis, in relation to the 1–5–10 years graft survival.</p

Graft survival after early or late primary Retransplantations.

<p>Graft survival after early or late primary Retransplantations.</p

Kaplan Meier curve for cumulative incidence of thrombosis after liver transplantation.

<p>Kaplan Meier curve for cumulative incidence of thrombosis after liver transplantation.</p

Distribution of the category variables in first retransplantations in relation to survival prospects, by means of univariate analysis (Kaplan-Meier, Log-Rank test).

<p>Distribution of the category variables in first retransplantations in relation to survival prospects, by means of univariate analysis (Kaplan-Meier, Log-Rank test).</p

Donor, transplant and recipient charachteristics in 184 retransplantations as continuous or discrete data.

<p>AST means serum glutamic oxaloacetic transaminase; ALT, alanine transaminase; ECC, Extracorporeal circulation; LT, Liver Transplantation; HCC, Hepatocarcinoma; FHF, Fulminant Hepatic Failure; HAT, Hepatic Artery Thrombosis; PNF, Primary non Function; HCV, hepatitis C Virus; INR, International Normalized Ratio; MELD, Mayo End stage Liver Disease; UNOS, United Network for Organ Sharing.</p

Results of multivariate cox regression analysis performed on selected variables related to graft failure after first liver retransplantations.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046643#s3" target="_blank">Results</a> of multivariate cox regression analysis performed on selected variables related to graft failure after first liver retransplantations.</p

Characteristics of patients included in the nested case-control study.

<p>Characteristics of patients included in the nested case-control study.</p

Flow-chart of the study population of patients with hepatocellular carcinoma.

<p>Flow-chart of the study population of patients with hepatocellular carcinoma.</p

Additional file 1: of Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis

Table S1. Characteristics of unmatched and matched treatment groups; The table shows the characteristics of patients who underwent TARE or sorafenib in unmatched and matched cohorts. (DOCX 14 kb

Incidence rates of mortality and need of re-transplantation in patients with or without thrombosis.

<p>Incidence rates of mortality and need of re-transplantation in patients with or without thrombosis.</p